Acurx Pharmaceuticals, Inc. Common Stock
$1.39
Market Cap
$5.97M
Shares Outstanding
4.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 25, 2021
Round Lot
100
Locale
US
Day Open
$1.36
Day High
$1.42
Day Low
$1.36
Volume
57.4K
VWAP
$1.40
Prev Close
$1.39
Transactions
--
Acc. Volume
--
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Acurx Pharmaceuticals, Inc. Common Stock (ACXP) closed the 2026-09-18 session at $1.39, up 0.00% versus the previous close (+0.00). The stock opened at $1.36 and traded between $1.36 and $1.42 during that session. Session trading volume was 57K shares. The volume-weighted average price (VWAP) is $1.40.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Acurx Pharmaceuticals, Inc. Common Stock has a market capitalization of $6.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ACXP is listed on the XNAS exchange. The company employs approximately 4 people. Acurx Pharmaceuticals, Inc. Common Stock is headquartered in STATEN ISLAND, NY. The recorded listing date is 2021-06-25.
On this page you can find market ACXP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.